164 related articles for article (PubMed ID: 32407112)
1. Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.
Mackman RL; Mish M; Chin G; Perry JK; Appleby T; Aktoudianakis V; Metobo S; Pyun P; Niu C; Daffis S; Yu H; Zheng J; Villasenor AG; Zablocki J; Chamberlain J; Jin H; Lee G; Suekawa-Pirrone K; Santos R; Delaney WE; Fletcher SP
J Med Chem; 2020 Sep; 63(18):10188-10203. PubMed ID: 32407112
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects.
Reyes M; Lutz JD; Lau AH; Gaggar A; Grant EP; Joshi A; Mackman RL; Ling J; Tan SK; Ayithan N; Daffis S; Woo J; Wu P; Lam T; Fletcher SP; Kottilil S; Poonia B; Gane EJ; Mathias A; German P
Antivir Ther; 2020; 25(3):171-180. PubMed ID: 32667286
[TBL] [Abstract][Full Text] [Related]
3. Follicular Helper T (T
Ayithan N; Tang L; Tan SK; Chen D; Wallin JJ; Fletcher SP; Kottilil S; Poonia B
Front Immunol; 2021; 12():735913. PubMed ID: 34512670
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators.
Amin OE; Colbeck EJ; Daffis S; Khan S; Ramakrishnan D; Pattabiraman D; Chu R; Micolochick Steuer H; Lehar S; Peiser L; Palazzo A; Frey C; Davies J; Javanbakht H; Rosenberg WMC; Fletcher SP; Maini MK; Pallett LJ
Hepatology; 2021 Jul; 74(1):55-71. PubMed ID: 33368377
[TBL] [Abstract][Full Text] [Related]
5. Oral Selective TLR8 Agonist Selgantolimod Induces Multiple Immune Cell Responses in Humans.
Ayithan N; Ghosh A; Dwivedi A; Wallin JJ; Tan SK; Chen D; Kottilil S; Poonia B
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960669
[TBL] [Abstract][Full Text] [Related]
6. Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B.
Daffis S; Balsitis S; Chamberlain J; Zheng J; Santos R; Rowe W; Ramakrishnan D; Pattabiraman D; Spurlock S; Chu R; Kang D; Mish M; Ramirez R; Li L; Li B; Ma S; Hung M; Voitenleitner C; Yon C; Suresh M; Menne S; Cote P; Delaney WE; Mackman R; Fletcher SP
Hepatology; 2021 Jan; 73(1):53-67. PubMed ID: 32246499
[TBL] [Abstract][Full Text] [Related]
7. Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B.
Gane EJ; Kim HJ; Visvanathan K; Kim YJ; Nguyen AH; Wallin JJ; Chen DY; McDonald C; Arora P; Tan SK; Gaggar A; Roberts SK; Lim YS
Hepatology; 2021 Oct; 74(4):1737-1749. PubMed ID: 33704806
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
[TBL] [Abstract][Full Text] [Related]
9. Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B.
McGowan DC; Herschke F; Pauwels F; Stoops B; Smyej I; Last S; Pieters S; Embrechts W; Khamlichi MD; Thoné T; Van Schoubroeck B; Mostmans W; Wuyts D; Verstappen D; Scholliers A; De Pooter D; Dhuyvetter D; Borghys H; Tuefferd M; Arnoult E; Hong J; Fanning G; Bollekens J; Urmaliya V; Teisman A; Horton H; Jonckers THM; Raboisson P
J Med Chem; 2017 Jul; 60(14):6137-6151. PubMed ID: 28671847
[TBL] [Abstract][Full Text] [Related]
10. 2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus.
Embrechts W; Herschke F; Pauwels F; Stoops B; Last S; Pieters S; Pande V; Pille G; Amssoms K; Smyej I; Dhuyvetter D; Scholliers A; Mostmans W; Van Dijck K; Van Schoubroeck B; Thone T; De Pooter D; Fanning G; Jonckers THM; Horton H; Raboisson P; McGowan D
J Med Chem; 2018 Jul; 61(14):6236-6246. PubMed ID: 29965759
[TBL] [Abstract][Full Text] [Related]
11. Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus.
McGowan D; Herschke F; Pauwels F; Stoops B; Last S; Pieters S; Scholliers A; Thoné T; Van Schoubroeck B; De Pooter D; Mostmans W; Khamlichi MD; Embrechts W; Dhuyvetter D; Smyej I; Arnoult E; Demin S; Borghys H; Fanning G; Vlach J; Raboisson P
J Med Chem; 2016 Sep; 59(17):7936-49. PubMed ID: 27513093
[TBL] [Abstract][Full Text] [Related]
12. TLR8 agonist partially improves IFN-γ deficiency of NK cells in chronic hepatitis B through the synergy of monocytes.
Ao X; Gan Q; Huang X; Bao D; Wu X; Lin Q; Lin A; Ding Y; Wang L; Chen Y; Huang Z
Aliment Pharmacol Ther; 2023 Feb; 57(4):387-398. PubMed ID: 36585909
[TBL] [Abstract][Full Text] [Related]
13. Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN-α-2a antiviral therapy.
Deng G; Ge J; Liu C; Pang J; Huang Z; Peng J; Sun J; Hou J; Zhang X
Clin Res Hepatol Gastroenterol; 2017 Sep; 41(4):386-398. PubMed ID: 28236535
[TBL] [Abstract][Full Text] [Related]
14. Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.
Beesu M; Salyer AC; Brush MJ; Trautman KL; Hill JK; David SA
J Med Chem; 2017 Mar; 60(5):2084-2098. PubMed ID: 28146629
[TBL] [Abstract][Full Text] [Related]
15. Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
Roethle PA; McFadden RM; Yang H; Hrvatin P; Hui H; Graupe M; Gallagher B; Chao J; Hesselgesser J; Duatschek P; Zheng J; Lu B; Tumas DB; Perry J; Halcomb RL
J Med Chem; 2013 Sep; 56(18):7324-33. PubMed ID: 23961878
[TBL] [Abstract][Full Text] [Related]
16. Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
Ren Q; Liu X; Luo Z; Li J; Wang C; Goldmann S; Zhang J; Zhang Y
Bioorg Med Chem; 2017 Feb; 25(3):1042-1056. PubMed ID: 28082068
[TBL] [Abstract][Full Text] [Related]
17. Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy.
Wang Z; Gao Y; He L; Sun S; Xia T; Hu L; Yao L; Wang L; Li D; Shi H; Liao X
J Med Chem; 2021 Jun; 64(11):7507-7532. PubMed ID: 34048243
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.
Kandimalla ER; Struthers M; Bett AJ; Wisniewski T; Dubey SA; Jiang W; Precopio M; Sun Z; Wang H; Lan T; Agrawal S; Casimiro DR
Cell Immunol; 2011; 270(2):126-34. PubMed ID: 21570062
[TBL] [Abstract][Full Text] [Related]
19. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.
Lanford RE; Guerra B; Chavez D; Giavedoni L; Hodara VL; Brasky KM; Fosdick A; Frey CR; Zheng J; Wolfgang G; Halcomb RL; Tumas DB
Gastroenterology; 2013 Jun; 144(7):1508-17, 1517.e1-10. PubMed ID: 23415804
[TBL] [Abstract][Full Text] [Related]
20. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8.
Lan T; Kandimalla ER; Yu D; Bhagat L; Li Y; Wang D; Zhu F; Tang JX; Putta MR; Cong Y; Trombino AF; Sullivan T; Agrawal S
Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13750-5. PubMed ID: 17698957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
